Ecnoglutide vs Semaglutide: 20-Week Phase 2 Weight Loss
A new head-to-head study suggests ecnoglutide may outperform semaglutide for weight loss. We break down the 20-week data and what it means for future treatment.
Ecnoglutide vs Semaglutide: 20-Week Phase 2 Weight Loss
Featured-snippet summary: A 20-week, randomized Phase 2 trial presented at the American Diabetes Association (ADA) 2026 Scientific Sessions showed adults with obesity who received once-weekly cAMP-biased ecnoglutide lost an average 12.8% of baseline body weight compared with 9.5% in the semaglutide 2.4 mg arm, a statistically significant 3.3-percentage-point advantage.[1]
Last updated August 2026
- Study design: Open-label, active-controlled, 20-week Phase 2 trial (n = 312)
- Primary endpoint: Percent change in body weight from baseline to Week 20
- Mean weight loss: −12.8% with ecnoglutide vs −9.5% with semaglutide[1]
- Most common adverse events: Mild–moderate gastrointestinal events; lower nausea with ecnoglutide (13.4% vs 21.0%)[1]
- Mechanism: Ecnoglutide is a cAMP-biased GLP-1 receptor agonist designed to favor G-protein signaling and reduce β-arrestin recruitment[4]
- Regulatory status: Not yet FDA-approved; Phase 3 obesity program underway
- Ecnoglutide produced a clinically meaningful 12.8% mean weight reduction in just 20 weeks.[1]
- The agent achieved this with similar overall gastrointestinal tolerability and less nausea than semaglutide.[1]
- Its cAMP-biased design may prolong appetite suppression while minimizing receptor desensitization.[4]
- Larger, longer Phase 3 trials are needed before FDA review.
- Current FDA-approved options like semaglutide and tirzepatide remain first-line until ecnoglutide completes trials.
What Did the Phase 2 Trial Compare?
The multicenter study randomized 156 adults to once-weekly ecnoglutide 2.0 mg and 156 to semaglutide 2.4 mg (Wegovy) for 20 weeks. Participants had a mean age of 45 years, body-mass index (BMI) 37 kg/m2, and no diabetes. Lifestyle counseling was standardized in both arms. The primary endpoint was percent change in body weight; secondary endpoints included proportions achieving ≥5%, ≥10%, and ≥15% weight loss and changes in cardiometabolic markers.[1]
How Much More Weight Did Ecnoglutide Help Lose?
At Week 20, ecnoglutide achieved a least-squares mean (LSM) weight reduction of −12.8% versus −9.5% with semaglutide, translating to an absolute difference of −3.3 percentage points (P < 0.0001).[1] The advantage was evident as early as Week 8 and widened through Week 20, suggesting a faster onset of effect.
| Endpoint (Week 20) | Ecnoglutide 2.0 mg (n = 151) | Semaglutide 2.4 mg (n = 150) |
|---|---|---|
| Mean % weight change (LSM) | −12.8 % (95 % CI −13.7 to −11.8) | −9.5 % (95 % CI −10.4 to −8.5) |
| ≥5 % weight-loss responders | 88 % | 77 % |
| ≥10 % responders | 54 % | 38 % |
| ≥15 % responders | 19 % | 11 % |
| Systolic BP change (mm Hg) | −5.6 | −4.2 |
For context, the landmark STEP 1 trial of semaglutide 2.4 mg reported a 14.9 % mean weight loss at 68 weeks.[2] Achieving 86 % of that reduction in less than one-third the time underscores ecnoglutide’s potential potency, though durability beyond 20 weeks is unproven.
What Makes Ecnoglutide cAMP-Biased and Why Does That Matter?
Ecnoglutide is engineered to preferentially trigger cyclic adenosine monophosphate (cAMP) signaling after binding the GLP-1 receptor while sparing β-arrestin recruitment and receptor internalization.[4] Pre-clinical data show:
- cAMP EC50 = 0.018 nM (high potency)
- β-arrestin recruitment EC50 > 10 µM (minimal)
- Extended half-life via C-terminal acylation for once-weekly dosing
This bias may extend receptor availability on cell surfaces, sustaining anorectic signaling and potentially reducing gastrointestinal adverse events linked to β-arrestin pathways. Similar bias strategies are being explored with other investigational peptides and small molecules.
How Safe Were Both Drugs at 20 Weeks?
Overall treatment-emergent adverse events (TEAEs) were comparable (ecnoglutide 79 % vs semaglutide 82 %). Gastrointestinal events dominated but were mostly mild or moderate.
| Adverse Event | Ecnoglutide (%) | Semaglutide (%) |
|---|---|---|
| Diarrhea | 30.5 | 30.9 |
| Nausea | 13.4 | 21.0 |
| Constipation | 17.1 | 11.1 |
| Vomiting | 11.0 | 12.3 |
| Serious AEs | 0.7 | 0.7 |
| Discontinuation due to AEs | 2.0 | 3.3 |
The lower rate of nausea with ecnoglutide aligns with its cAMP-biased design, though constipation occurred slightly more often.[1] No pancreatitis, medullary thyroid carcinoma, or severe hypoglycemia was reported. Long-term safety, including gallbladder events and renal outcomes, awaits Phase 3 data.
Could Ecnoglutide Change Future Obesity Treatment?
More than four in ten U.S. adults live with obesity, according to 2024 CDC maps that show at least 35 % prevalence in 23 states.[5] Given this public-health burden, even incremental efficacy gains are welcome. A consistent 3-percentage-point advantage could translate into roughly 7–10 extra pounds for a 300-pound individual.
If Phase 3 trials confirm superiority without new safety concerns, ecnoglutide could:
- Offer an alternative for patients who plateau or cannot tolerate semaglutide
- Drive competition that may lower costs or improve access
- Reinforce the therapeutic value of signal-biased drug design
How Does It Stack Up Against Tirzepatide and Other GLP-1s?
The dual GIP/GLP-1 agonist tirzepatide delivered 15–21 % mean weight reductions at 72 weeks in SURMOUNT-1.[6] Because ecnoglutide data are limited to 20 weeks, direct comparisons are premature. Still, a few points help frame expectations:
- Onset speed: Ecnoglutide’s 12.8 % loss in 20 weeks rivals tirzepatide’s 11.9 % placebo-adjusted loss at 72 weeks (5 mg dose).
- Mechanism: Tirzepatide’s dual incretin activity may confer added glycemic and weight benefits but can increase GI side effects. Ecnoglutide leverages bias within a single receptor pathway.
- Dosing: Both are once weekly injections; oral formulations of semaglutide exist, and oral ecnoglutide analogs are under investigation.
- Regulatory timeline: Tirzepatide is FDA-approved for diabetes and obesity, whereas ecnoglutide remains investigational.
What Are the Limitations of the Data?
Key caveats include:
- Short duration: Twenty weeks is insufficient to evaluate long-term weight maintenance, cardiovascular outcomes, or rare AEs.
- Open-label design: Lack of blinding can bias subjective endpoints such as tolerability.
- No lifestyle run-in: Participants began medication soon after randomization, limiting assessment of lifestyle-only baseline changes.
- Single dose level: Higher or lower ecnoglutide doses may yield different efficacy–safety balances.
- Diversity: The cohort was 68 % female and 71 % White, which may not reflect the broader U.S. obesity population.
When Might Ecnoglutide Be Available?
Sciwind Biosciences has launched a global Phase 3 obesity program expected to complete primary readout in late 2027. Given typical FDA review timelines, U.S. approval could arrive in 2028–2029 if results are favorable. Until then, FDA-approved options such as semaglutide (Wegovy) and tirzepatide (Zepbound) remain the standard of care.[3]
Choosing Between Current GLP-1 Options
| Factor | Semaglutide | Tirzepatide | Ecnoglutide (Investigational) |
|---|---|---|---|
| Average weight loss | 14.9 % at 68 weeks (STEP 1)[2] | 15–21 % at 72 weeks (SURMOUNT-1)[6] | 12.8 % at 20 weeks (Phase 2)[1] |
| Most common AE | Nausea 20–44 %[3] | Nausea 24–32 %[6] | Diarrhea 30 %[1] |
| Cardiovascular benefit | Yes (SELECT trial) | CVOT ongoing | Unknown |
| FDA status | Approved 2021 | Approved 2024 | Phase 3 |
When to Contact Your Healthcare Provider
- Persistent or severe nausea, vomiting, or abdominal pain
- Signs of dehydration (dizziness, reduced urination)
- Symptoms of gallbladder disease (fever, right-upper-quadrant pain)
- Possible pancreatitis (severe stomach pain radiating to the back)
- Vision changes or signs of diabetic retinopathy worsening
- Lump or swelling in the neck (possible thyroid abnormality)
Scientific References
- Zhu X, Wang W, et al. Efficacy and Safety of cAMP-Biased Ecnoglutide vs Unbiased Semaglutide in Adults With Obesity: 20-Week Results From a Multicenter, Randomized, Open-Label, Phase 2 Study. Diabetes. 2026;75(Suppl 1):2849-LB.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. N Engl J Med. 2021;384:989-1002. DOI:10.1056/NEJMoa2032183.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Injection Prescribing Information. DailyMed; revised 2026.
- Guo W, Xu Z, Zou H, et al. Discovery of Ecnoglutide: A Novel, Long-Acting, cAMP-Biased GLP-1 Analog. Mol Metab. 2023;75:101762. DOI:10.1016/j.molmet.2023.101762.
- Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. Updated September 2024. Accessed July 2026.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-215. DOI:10.1056/NEJMoa2206038.
Source: FDA-approved prescribing information for semaglutide (Wegovy)
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
